BioMarin Pharmaceutical and Ascendis Pharma settled global patent disputes over Yuviwel, granting BioMarin significant royalty payments.

BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

Ascendis pagará à BioMarin 20% das vendas líquidas do Yuviwel nos EUA, retroativos à primeira venda comercial, e de 18% das vendas líquidas na União Europeia, na Coreia do Sul e…